Targeting PRMT5 through PROTAC for the treatment of triple-negative breast cancer.
Guo Y, Li Y, Zhou Z, Hou L, Liu W, Ren W, Mi D, Sun J, Dai X, Wu Y, Cheng Z, Wu T, Luo Q, Tian C, Li F, Yu Z, Chen Y, Chen C.
Guo Y, et al. Among authors: chen y.
J Exp Clin Cancer Res. 2024 Nov 30;43(1):314. doi: 10.1186/s13046-024-03237-y.
J Exp Clin Cancer Res. 2024.
PMID: 39614393